189 filings
Page 4 of 10
8-K
9ps8dkgzmk yg
1 Jun 20
Regulation FD Disclosure
9:22am
8-K
pb66f488psue49
29 May 20
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical
8:17am
8-K
n8tcvze6vbem6dy2wqsa
21 May 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
76d63y9pk18g4lk30t
11 May 20
Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results
4:17pm
8-K
s97ic ntumrjcmgmsd
29 Apr 20
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
4:17pm
8-K
bf6y4
12 Mar 20
Marker Therapeutics Reports Full Year 2019 Operating and Financial Results
4:38pm
8-K
sy7 smwitx1riweoo
2 Mar 20
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
9:03am
8-K
4kop4m rq7z7
11 Feb 20
Marker Therapeutics Announces Update to its Clinical Program in AML
7:00am
8-K
p82x4s3g gaagztxzq
12 Nov 19
Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results
4:16pm
8-K
vym80bpyz7f
24 Sep 19
Regulation FD Disclosure
4:06pm
8-K
texq 4gtpzmuku8
15 Aug 19
Regulation FD Disclosure
4:17pm
8-K
03tjjc
9 Aug 19
Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results
6:03am
8-K
dr0n dbtrxegrj9bgt8
6 Aug 19
Marker Therapeutics Appoints Steve Elms to its Board of Directors
4:48pm
8-K
rt38hy95hblxqn 8m6p
22 Jul 19
Regulation FD Disclosure
8:35am
8-K
kx9tve9szd9u49
19 Jul 19
Regulation FD Disclosure
9:14am
8-K
2tslmzd9wz
20 Jun 19
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
7:05am
8-K
uv9j613 6exyvtb
10 May 19
Submission of Matters to a Vote of Security Holders
5:05pm
8-K
zkaowun3 nvv33
9 May 19
Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results
5:07pm
8-K
3cowtlo
17 Apr 19
Other Events
7:00am
8-K
lai9mh0h
28 Mar 19
Marker Therapeutics Provides Business and Clinical Update
5:09pm